Project Grant HT94252311018

This $1,253,527 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop and validate a novel 3D in vitro brain organoid platform for modeling genetic and sporadic subtypes of Frontotemporal Dementia (FTD). The grantee, Synapticure Inc., a for-profit organization, will generate and validate "Cortical Brain...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a novel blood-based diagnostic test for early diagnosis and classification of frontotemporal lobar degeneration (FTD). The $638,854 award to Virtici LLC, a for-profit biomedical research company in Seattle, will fund the development of a low-volume, antibody-based assay to...

This $459,525 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports Aperture Therapeutics, Inc. in rapidly discovering a novel oligonucleotide therapeutic for direct modulation of a genetically validated target involved in pathologic neuroinflammation. The project aims to leverage Aperture's high-throughput iPSC platform with diverse genetic models of frontotemporal dementia (FTD) to provide robust functional evidence for further development...

The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), has awarded a $869,959 Cooperative Agreement to The Regents of the University of California, San Francisco to develop a safe and effective genome editing therapy to treat frontotemporal dementia caused by the C9ORF72 gene mutation. The project aims to optimize a CRISPR/Cas9 genome editing strategy to excise the C9ORF72 repeat...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a new antisense oligonucleotide (ASO) therapeutic for Dravet syndrome. The $391,903 award aims to characterize the pharmacokinetics and pharmacodynamics of this ASO, which targets a mechanism to directly increase the Nav1.1 protein expression and...

Acurastem Inc. received a $839,898.40 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an UNC13A antisense oligonucleotide treatment for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) from June 1, 2023 to May 31, 2025. The grant funding will support Acurastem's efforts to advance a novel gene therapy targeting UNC13A, a gene implicated in ALS and FTD, using antisense oligonucleotide...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will fund the development and validation of a novel, cellularly complex human induced pluripotent stem cell (iPSC)-based model of frontotemporal dementia (FTD) due to mutations in the MAPT gene that encodes the tau protein. The $1,540,579 award to the Regenerative Research...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,041,646.00 to Cenna Biosciences Inc. to support the early clinical development of a novel peptide drug candidate, modified P8 (MP8), for the treatment of Alzheimer's disease. The award will fund activities to enable a first-in-human clinical study, including CMC work, a pre-IND meeting with the FDA, IND submission, and the execution of Phase 1 clinical trials of MP8. The project aims to...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting the development and optimization of a new animal model for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The $374,349 award to the University of North Carolina at Chapel Hill aims to demonstrate the progressive ALS/FTD-like phenotype in aged cohorts of...